Stock AMGN AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Amgen Inc.

Equities

AMGN

US0311621009

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
305.8 USD -0.22% Intraday chart for Amgen Inc. -2.12% +6.19%
May. 22 Sandoz: Marketing authorization for Wyost and Jubbonti in the EU CF
May. 22 Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Amgen : An Underrecognized Risk Factor for Heart Disease
PU
Improving treatment responses to solid tumours with trispecific TCEs
AQ
Amgen : From the Office to the Lab, Amgen Uses AI Tools to Unlock Innovation
PU
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU
CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test
MT
Amgen : Actress and Producer Gina Torres Urges Hispanic Americans to Prioritize Cholesterol Care
PU
Amgen : At Milken Global Conference, Bradway Calls for Protecting U.S. Policy Ecosystem That Fosters Innovation
PU
Driving Long-Term Growth: IMDELLTRA™ Approval and Information Update Presentation
PU
Transcript : Amgen Inc. - Special Call
Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
AQ
AMGEN - NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE TO HELP PATIENTS LIVING WITH COPD
AQ
HSBC Adjusts Price Target on Amgen to $356 From $322
MT
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results
MT
Amgen And Sandoz Settle Denosumab BPCIA Litigation
AQ
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
CI
US FDA approves Amgen drug for small cell lung cancer
RE
Amgen : Expanding Innovation in BiTE® Technology for Patients with Extensive Stage Small Cell Lung Cancer (ES SCLC)
PU
FDA Approves Amgen's IMDELLTRA?? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer
CI
Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment
DJ
Amgen's Imdelltra Gets US FDA Accelerated Approval for Drug to Treat Extensive Stage Small Cell Lung Cancer
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. News Amgen Inc.